Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Chakraborty S, Rahman T. The difficulties in cancer treatment Ecancermedicalscience. 2012;6:ed16.

PubMed  Google Scholar 

Pourgholi A, Dadashpour M, Mousapour A, Amandi AF, Zarghami N. Anticancer potential of silibinin loaded polymeric nanoparticles against breast cancer cells: insight into the apoptotic genes targets. Asian Pacific Journal of Cancer Prevention: APJCP. 2021;22(8):2587.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience. 2019;13:961.

Article  PubMed  PubMed Central  Google Scholar 

Charmsaz S, Collins DM, Perry AS, Prencipe M. Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference. Cancers. 2019;11(8):1125.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alagheband Y, Jafari-gharabaghlou D, Imani M, Mousazadeh H, Dadashpour M, Firouzi-Amandi A, et al. Design and fabrication of a dual-drug loaded nano-platform for synergistic anticancer and cytotoxicity effects on the expression of leptin in lung cancer treatment. Journal of Drug Delivery Science and Technology. 2022;73: 103389.

Article  CAS  Google Scholar 

Makhoba XH, Viegas C Jr, Mosa RA, Viegas FPD, Pooe OJ. Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases. Drug Des Devel Ther. 2020;14:3235–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769–92.

Article  PubMed  PubMed Central  Google Scholar 

Joo WD, Visintin I, Mor G. Targeted cancer therapy–are the days of systemic chemotherapy numbered? Maturitas. 2013;76(4):308–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan L, Rosen N, Arteaga C. Targeted cancer therapies. Chin J Cancer. 2011;30(1):1–4.

Article  PubMed  PubMed Central  Google Scholar 

Makhoba XH, Viegas C Jr, Mosa RA, Viegas FPD, Pooe OJ. Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases. Drug Des Dev Ther. 2020;14:3235–49.

Article  CAS  Google Scholar 

Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol. 2013;6(1):41–7.

Article  CAS  PubMed  Google Scholar 

Talevi A. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front Pharmacol. 2015;6:156790.

Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008;77(3):311–9.

PubMed  Google Scholar 

Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201.

Article  PubMed  PubMed Central  Google Scholar 

Montoya S, Soong D, Nguyen N, Affer M, Munamarty SP, Taylor J. Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines. 2021;9(11):1591.

Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43.

Article  PubMed  Google Scholar 

DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151–85.

Article  PubMed  Google Scholar 

He B, Lu C, Zheng G, He X, Wang M, Chen G, et al. Combination therapeutics in complex diseases. J Cell Mol Med. 2016;20(12):2231–40.

Article  PubMed  PubMed Central  Google Scholar 

Towards a solution for the access challenges faced by combination treatments 2021 [Available from: https://www.europeanpharmaceuticalreview.com/article/164000/towards-a-solution-for-the-access-challenges-faced-by-combination-treatments/.

Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2017;14(1):57–66.

Article  CAS  PubMed  Google Scholar 

Brindisi M, Kessler SM, Kumar V, Zwergel C. Editorial: Multi-target directed ligands for the treatment of cancer. Front Oncol. 2022;12:980141.

Rodríguez-Soacha DA, Scheiner M, Decker M. Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands. Eur J Med Chem. 2019;180:690–706.

Article  PubMed  Google Scholar 

Alcaro S, Bolognesi ML, García-Sosa AT, Rapposelli S. Editorial: Multi-Target-Directed Ligands (MTDL) as Challenging Research Tools in Drug Discovery: From Design to Pharmacological Evaluation. Front Chem. 2019;7:71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gurung AB, Ali MA, Lee J, Farah MA, Al-Anazi KM. An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19. Biomed Res Int. 2021;2021:8853056.

Article  PubMed  PubMed Central  Google Scholar 

McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15–26.

Article  CAS  PubMed  Google Scholar 

Shi Z-D, Pang K, Wu Z-X, Dong Y, Hao L, Qin J-X, et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther. 2023;8(1):113.

Article  PubMed  PubMed Central  Google Scholar 

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26.

Article  CAS  PubMed  Google Scholar 

Firouzi Amandi A, Jokar E, Eslami M, Dadashpour M, Rezaie M, Yazdani Y, et al. Enhanced anti-cancer effect of artemisinin-and curcumin-loaded niosomal nanoparticles against human colon cancer cells. Med Oncol. 2023;40(6):170.

Article  CAS  PubMed  Google Scholar 

Jafari-Gharabaghlou D, Dadashpour M, Khanghah OJ, Salmani-Javan E, Zarghami N. Potentiation of Folate-Functionalized PLGA-PEG nanoparticles loaded with metformin for the treatment of breast Cancer: possible clinical application. Mol Biol Rep. 2023;50(4):3023–33.

Article  CAS  PubMed  Google Scholar 

Amirsaadat S, Jafari-Gharabaghlou D, Dadashpour M, Zarghami N. Potential anti-proliferative effect of nano-formulated curcumin through modulating micro RNA-132, Cyclin D1, and hTERT genes expression in breast cancer cell lines. Journal of Cluster Science. 2023;34:2537–46.

Article  CAS  Google Scholar 

Ayoub NM. Editorial: Novel Combination Therapies for the Treatment of Solid Cancers. Front Oncol. 2021;11:708943

Palmer AC, Chidley C, Sorger PK. A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. eLife. 2019;8.

Firouzi-Amandi A, Tarahomi M, Rahmani-Youshanlouei H, Heris RM, Jafari-Gharabaghlou D, Zarghami N, et al. Development, characterization, and in vitro evaluation of cytotoxic activity of Rutin loaded PCL-PEG nanoparticles against Skov3 ovarian cancer cell. Asian Pacific Journal of Cancer Prevention: APJCP. 2022;23(6):1951.

Article  CAS  PubMed Central  Google Scholar 

Wei Q, Li P, Yang T, Zhu J, Sun L, Zhang Z, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011;103(16):1222–6.

Article  CAS  PubMed  Google Scholar 

Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, et al. Cobimetinib plus atezolizumab in BRAF(V600) wild-type melanoma: primary results from the randomized phase III IMspire170 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2021;32(3):384–94.

Article  CAS  PubMed  Google Scholar 

Özdemir D, Büssgen M. Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma. Journal of pharmaceutical policy and practice. 2023;16(1):106.

Article  PubMed  PubMed Central  Google Scholar 

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.

Article  PubMed  Google Scholar 

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.

Article  CAS  PubMed  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40(2):127–37.

Article  CAS  PubMed